Ascorbic Pharma is a globally focused clinical-stage biotechnology company dedicated to developing novel therapies for cancer, the hepatitis B virus, and age-related diseases. The company focuses on developing treatments that inhibit protein-protein interactions to restore apoptosis or programmed cell death. Ascorbic Pharma has established new products including eight drug candidates, including novel, highly effective Bcl-2/Bcl-XL inhibitors, candidates targeting the IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. The company has conducted 28 phase I/II clinical trials to evaluate eight products from the US, Australia, and China to develop potential treatments as single drugs or combination drugs.
No Data
No Data